上海勁馬實(shí)驗(yàn)設(shè)備有限公司作者
人乳腺癌細(xì)胞株 4T1
資料類型 | doc文件 | 資料大小 | 30208 |
下載次數(shù) | 115 | 資料圖片 | 【點(diǎn)擊查看】 |
上 傳 人 | 上海勁馬實(shí)驗(yàn)設(shè)備有限公司 | 需要積分 | 0 |
關(guān) 鍵 詞 | 乳腺癌細(xì)胞株,4T1 |
- 【資料簡(jiǎn)介】
- 上海勁馬實(shí)驗(yàn)設(shè)備有限公司是一家專業(yè)從事免疫學(xué)、細(xì)胞學(xué)、化學(xué)試劑代理商,現(xiàn)在本公司可代理美國(guó)ATCC細(xì)胞、美國(guó)Sciencell細(xì)胞,美國(guó)CHI細(xì)胞,同事我公司也有種類齊全的傳代細(xì)胞,所有細(xì)胞都附有傳代情況及培養(yǎng)說(shuō)明。我公司現(xiàn)在與美國(guó)公司合作,接受客戶原代細(xì)胞定做,只限于人和小鼠正常組織細(xì)胞,細(xì)胞zui小量100萬(wàn)個(gè),歡迎有需要的客戶前來(lái)咨詢。 : 何人乳腺癌細(xì)胞株 4T1Price: $279.00Designations: 4T1Depositors: BA PulaskiBiosafety Level: 1Shipped: frozenMedium & Serum: See PropagationGrowth Properties: adherentOrganism: Mus musculus (mouse)Morphology: epithelialSource: Organ: mammary glandStrain: BALB/cfC3HDisease: tumorPermits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.Tumorigenic: YesComments: 4T1 is a 6-thioguanine resistant cell line selected from the 410.4 tumor without mutagen treatment. [49690]When injected into BALB/c mice, 4T1 spontaneously produces highly metastatic tumors that can metastasize to the lung, liver, lymph nodes and brain while the primary tumor is growing in situ. [49688] [49690]The primary tumor does not have to be removed to induce metastatic growth.The tumor growth and metastatic spread of 4T1 cells in BALB/c mice very closely mimic human breast cancer. This tumor is an animal model for stage IV human breast cancer. [49688] [49689]4T1-induced tumors can be used as a post-operative model as well as a non-surgical model because the 4T1-induced tumor metastasizes spontaneously in both models with similar kinetics. [49687] [49688] [49689]Because 4T1 is resistant to 6-thioquanine, micro-metastatic cells (as few as 1) can be detected in many distant site organs with better accuracy that most tumor models. There is no need to count nodules or weight target organs. [49687] [49688] [49689]Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.Temperature: 37.0°CAtmosphere: air, 95%; carbon dioxide (CO2), 5%Subculturing: Protocol: NOTE: the cells should not be allowed to become confluent, subculture at 80% of confluence. Remove medium, and rinse with 0.25% trypsin-0.53mM EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37.0°C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.Subc*tion Ratio: A subc*tion ratio of 1:6 to 1:8 is recommendedMedium Renewal: Every 2 to 3 daysPreservation: Freeze medium: Complete growth medium 95%; DMSO, 5%Storage temperature: liquid nitrogen vapor temperatureRelated Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001recommended serum:ATCC 30-2020References: 49687: Pulaski BA, et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol. Immunother. 49: 34-45, 2000. PubMed: 1078286449688: Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493, 1998. PubMed: 953725249689: Pulaski BA, et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 60: 2710-2715, 2000. PubMed: 1082514549690: Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405, 1992. PubMed: 1540948
2024世環(huán)會(huì)【工業(yè)節(jié)能與環(huán)保展】

div6月3日,2024世環(huán)會(huì)【工業(yè)節(jié)能與環(huán)保展】于上海丨國(guó)家會(huì)展中[詳細(xì)]
- 凡本網(wǎng)注明"來(lái)源:環(huán)保在線"的所有作品,版權(quán)均屬于環(huán)保在線,轉(zhuǎn)載請(qǐng)必須注明環(huán)保在線,http://www.aboay.com。違反者本網(wǎng)將追究相關(guān)法律責(zé)任。
- 企業(yè)發(fā)布的公司新聞、技術(shù)文章、資料下載等內(nèi)容,如涉及侵權(quán)、違規(guī)遭投訴的,一律由發(fā)布企業(yè)自行承擔(dān)責(zé)任,本網(wǎng)有權(quán)刪除內(nèi)容并追溯責(zé)任。
- 本網(wǎng)轉(zhuǎn)載并注明自其它來(lái)源的作品,目的在于傳遞更多信息,并不代表本網(wǎng)贊同其觀點(diǎn)或證實(shí)其內(nèi)容的真實(shí)性,不承擔(dān)此類作品侵權(quán)行為的直接責(zé)任及連帶責(zé)任。其他媒體、網(wǎng)站或個(gè)人從本網(wǎng)轉(zhuǎn)載時(shí),必須保留本網(wǎng)注明的作品來(lái)源,并自負(fù)版權(quán)等法律責(zé)任。
- 如涉及作品內(nèi)容、版權(quán)等問(wèn)題,請(qǐng)?jiān)谧髌钒l(fā)表之日起一周內(nèi)與本網(wǎng)聯(lián)系,否則視為放棄相關(guān)權(quán)利。